An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
National Cancer Center Hospital East
National Cancer Center Hospital East
Baylor College of Medicine
Sichuan Baili Pharmaceutical Co., Ltd.
Asan Medical Center
Astellas Pharma Inc
Amgen
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Ruijin Hospital
ImmunityBio, Inc.
Nizhny Novgorod Regional Clinical Oncology Center
Merck Sharp & Dohme LLC
Asan Medical Center
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NuCana plc
Jiangsu Hansoh Pharmaceutical Co., Ltd.
The Netherlands Cancer Institute
OncoC4, Inc.
Ukrainian Society of Clinical Oncology
Fudan University
Australasian Gastro-Intestinal Trials Group
Alliance for Clinical Trials in Oncology
Yonsei University
BeiGene
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Krankenhaus Nordwest
Krankenhaus Nordwest
Ukrainian Society of Clinical Oncology
Johns Hopkins University
The Netherlands Cancer Institute
Sixth Affiliated Hospital, Sun Yat-sen University
University Hospital, Essen
Asan Medical Center
Menoufia University
Shanghai JMT-Bio Inc.
Shanghai University of Traditional Chinese Medicine
Sanofi
National Cheng-Kung University Hospital
Hebei Medical University
Chinese University of Hong Kong
The First Affiliated Hospital of Zhengzhou University
RenJi Hospital
Incyte Corporation
InxMed (Shanghai) Co., Ltd.
ChineseAMS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Shanghai Zhongshan Hospital
Hutchmed
Sixth Affiliated Hospital, Sun Yat-sen University